Literature DB >> 18668841

The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.

.   

Abstract

Serum concentrations of salicylazosulphapyridine (SASP), sulphapyridine (SP), and 5-aminosalicylic acid (5-ASA) were measured in 64 outpatients with ulcerative colitis. About 90% of the patients in remission had serum total SP concentrations above 20 mug/ml. Seven patients, however, had active disease despite a serum total SP concentration > 20 mug/ml. The SASP and the individual SP metabolites did not show any correlation with the disease state. Three g per day seems to be the most effective dose. Plain and enteric-coated tablets produced similar concentrations at equivalent dosage. Side effects due to SASP were frequent in patients who had a total SP concentration > 50 mug/ml of serum.

Entities:  

Year:  1973        PMID: 18668841      PMCID: PMC1412752          DOI: 10.1136/gut.14.8.637

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

3.  A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.

Authors:  C G MOERTEL; J A BARGEN
Journal:  Ann Intern Med       Date:  1959-11       Impact factor: 25.391

4.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

5.  Salazopyrin metabolism in ulcerative colitis.

Authors:  K M Das; M A Eastwood; J P Macmanus; W Sircus
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

6.  Ulcerative colitis. A clinical study of 399 patients.

Authors:  K N Jalan; R F Prestcott; W Sircus; W I Card; J P McManus; C W Falconer; W P Small; A N Smith; J Bruce
Journal:  J R Coll Surg Edinb       Date:  1971-11

7.  Determination of salicylazosulphapyridine in biological materials.

Authors:  M Sandberg; K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

8.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

9.  Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.

Authors:  K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

10.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

View more
  4 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.

Authors:  M E Sharp; S M Wallace; K W Hindmarsh; M A Brown
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

4.  Sulphasalazine and male infertility: reversibility and possible mechanism.

Authors:  S Toovey; E Hudson; W F Hendry; A J Levi
Journal:  Gut       Date:  1981-06       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.